TRCT
MENS

Tower Research Capital (TRC)’s Jyong Biotech MENS Stock Holding History

Tower Research Capital (TRC)’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.2K Buy
11,703
+6,918
+145% +$16.9K ﹤0.01% 3318
2025
Q4 		$18.9K Buy
4,785
+4,759
+18,304% +$168K ﹤0.01% 3136
2025
Q3 		$1.02K Buy
+26
New +$936 ﹤0.01% 4892

Other funds holding MENS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tower Research Capital (TRC)'s MENS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Jyong Biotech (MENS) stake by 145% in Q1 2026, buying an estimated $16.9K and bringing the position to 11,703 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3318.

Tower Research Capital (TRC) first reported a position in MENS in Q3 2025 and has held it in 3 quarters since. 17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

  • Tower Research Capital (TRC) held 11,703 shares of Jyong Biotech worth $25.2K as of Q1 2026.
  • Tower Research Capital (TRC) bought 6,918 Jyong Biotech shares in Q1 2026, an estimated $16.9K.
  • Jyong Biotech made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3318 holding.
  • Tower Research Capital (TRC) first reported a position in Jyong Biotech in Q3 2025 and has held it in 3 quarters since.
  • 17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.